SK Channels
Therapeutics / Small MoleculeOngoing, early-stage preclinical discovery (per CerebrumDAO's project page)
A small-molecule positive allosteric modulator of SK (small-conductance calcium-activated potassium) channels, targeting spinocerebellar ataxia type 2 and essential tremor.
The science
Problem
Ataxia and tremor disorders linked to SK-channel dysfunction.
Approach
Licensed small-molecule modulator technology; exclusive patent license from Chapman University per CerebrumDAO's page.
Why CerebrumDAO supported it
Not publicly documented beyond the project page's milestone plan (replication study, lead optimization, preclinical candidate).
Researchers & founders
- Peter Groenen, PhD (Project Lead / Principal Investigator, per CerebrumDAO's page)
- Dr. Maryna Polyakova (Science Lead)
- Brian Magierski (CEO)
Organizations
- Chapman University (exclusive patent license, per CerebrumDAO's page)